Key regions: France, Brazil, South Korea, India, China
The demand for antiviral drugs in Eastern Asia has been steadily increasing in recent years.
Customer preferences: Customers in Eastern Asia have shown a strong preference for antiviral drugs that are effective against a wide range of viruses. They also prefer drugs that have minimal side effects and are affordable. In addition, there is a growing demand for drugs that can be administered orally, rather than through injections.
Trends in the market: Japan is the largest market for antiviral drugs in Eastern Asia, followed by China and South Korea. The Japanese market is dominated by drugs that treat hepatitis B and C, while the Chinese market is dominated by drugs that treat HIV/AIDS. In South Korea, there is a growing demand for drugs that treat respiratory viruses, such as influenza.
Local special circumstances: In China, the government has been actively promoting the use of generic drugs, which has led to a decrease in the price of antiviral drugs. In addition, the Chinese government has launched several initiatives to combat HIV/AIDS, which has led to an increase in the demand for antiviral drugs that treat this disease. In Japan, the government has implemented strict regulations on the approval of new drugs, which has slowed down the introduction of new antiviral drugs to the market.
Underlying macroeconomic factors: The increasing prevalence of viral diseases in Eastern Asia, such as hepatitis B and C, HIV/AIDS, and influenza, has been a major driver of the demand for antiviral drugs in the region. In addition, the growing aging population in countries like Japan and South Korea has led to an increase in the demand for drugs that treat age-related diseases, such as hepatitis. The economic growth of countries like China has also led to an increase in healthcare spending, which has contributed to the growth of the antiviral drugs market in the region.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
